Jane Street Group, LLC Aprea Therapeutics, Inc. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 14, 2023	BUY	$0.32 - $15.2 $16,304 - $774,440	50,950 New	50,950 $16,000
Q2 2022 Aug 16, 2022	BUY	$0.62 - $1.94 $44,614 - $139,600	71,959 New	71,959 $54,000
Q1 2022 May 17, 2022	SELL	$1.59 - $3.16 $33,711 - $66,998	-21,202 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$2.87 - $5.58 $20,213 - $39,299	7,043 Added 49.74%	21,202 $61,000
Q3 2021 Nov 16, 2021	BUY	$3.43 - $5.63 $48,565 - $79,715	14,159 New	14,159 $72,000
Q1 2021 May 18, 2021	SELL	$4.73 - $8.15 $56,078 - $96,626	-11,856 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$4.92 - $30.67 $58,331 - $363,623	11,856 New	11,856 $58,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,822
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.